The extent of GSH depletion and the resulting cytotoxic effects can vary among different GBM cell lines, with U87/EGFRvIII cells exhibiting the most significant increase in ROS and the most pronounced cytotoxic response, suggesting that the presence of EGFR mutations may influence the effectiveness of GSH-targeting strategies [136]. The gene discussed is EGFR; the disease is glioblastoma.